Hutchison/MRC Research Centre

Recent papers from Hutchison/MRC Research Centre

1. HRDPath: an explainable multi-model deep learning architecture for predicting homologous recombination deficiency from histopathology imagesNature Communications · 2026
2. Cancer treatment alters mutant selection in normal esophagusNature Genetics · 2026
3. Sub-GHz breathing dynamics of magnetic hopfionsScientific Reports · 2026
4. Senescent Human Liver Endothelial Cells Mediate CD4 ⁺ T Cell Recruitment via ICOSLImmunology · 2026
5. Cancer-associated fibroblast subtypes differentially modulate natural killer cells in cancerCell Reports · 2026
6. Abstract 1223: Spatial transcriptomics identifies a suppressive T-cell excluded tumour microenvironment in extramedullary multiple myeloma.Cancer Research · 2026
7. BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemiaAnnals of Hematology · 2026
8. Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilitiesEMBO Molecular Medicine · 2025
9. Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repairNAR Cancer · 2025
10. Single-cell analysis of Barrett’s esophagus and carcinoma reveals cell types conferring risk via genetic predispositionCell Genomics · 2025
11. Cancer-associated fibroblasts are associated with neo-adjuvant treatment response in oesophageal adenocarcinomaBritish Journal of Cancer · 2025
12. Somatic mutations in TBX3 promote hepatic clonal expansion by accelerating VLDL secretionJournal of Clinical Investigation · 2025
13. Impact of mtG3PDH inhibitors on proliferation and metabolism of androgen receptor-negative prostate cancer cells: Role of extracellular pyruvatePLoS ONE · 2025
14. Mutation burden of narrowband ultraviolet B phototherapy (NB-UVB) in human skin: relevance to NB-UVB lifetime exposures and skin cancer surveillanceBritish Journal of Dermatology · 2025
15. Assessment of early response to neoadjuvant chemotherapy in multi-site high-grade serous ovarian cancer using hyperpolarized-13C MRIEJNMMI Research · 2025
16. Mechanistic basis for protection against fatty liver disease by CIDEB loss-of-function mutations2025
17. A morphometric signature to identify ductal carcinoma in situ with a low risk of progressionnpj Precision Oncology · 2025
18. Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair2025
19. Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancerNature Cancer · 2025
20. Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinomaScientific Reports · 2024